Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 21 NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5 Leukemia, Myeloid, Chronic-Phase 2 Leukemia, Myeloid, Acute 1 Leukemia, Myeloid, Accelerated Phase 1 Leukemia, Myeloid 1 Leukemia 1 Hematologic Tumors 1 Hematologic Neoplasms 1 Blast Crisis 1

Interventions

Azacitidine 142 Cytarabine 109 venetoclax 94 fludarabine 35 Daunorubicin 34 Decitabine 32 Idarubicin 26 gilteritinib 24 Cyclophosphamide 21 quizartinib 15 midostaurin 15 Mitoxantrone 14 Etoposide 14 Granulocyte Colony-Stimulating Factor 12 Gemtuzumab 11 CPX-351 11 decitabine and cedazuridine drug combination 10 Drug Therapy 10 cc-486 9 Filgrastim 9 Clofarabine 9 ivosidenib 8 Injections 8 Dexamethasone 8 pevonedistat 7 fludarabine phosphate 7 AP 1903 reagent 7 posaconazole 6 magrolimab 6 glasdegib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Leukemia, Myeloid, Acute × Homoharringtonine × Clear all

NCT04716114 2021-11-02

ALIVE

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡